Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04179032 · ClinicalTrials.gov registry record · Phase 2
Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)
A Phase 2 study of Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 11
- Study locations
NCT04179032: Active Phase 2 study of Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline.
NCT04179032 is a Phase 2 study of Systemic Lupus Erythematosus that is active but no longer recruiting, run by GlaxoSmithKline. The registered enrollment target is 25 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04179032, a Phase 2 study of Systemic Lupus Erythematosus, is active but no longer recruiting, sponsored by GlaxoSmithKline.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to 17 years of age with SLE on a background of standard of care therapy. This bridging PK study is part of an extrapolation strategy to support the use of SC belimumab in pediatric SLE participants, based on the completed adult SLE study with SC belimumab and the pediatric SLE study with intravenous (IV) belimumab. Part A is an open label 12-week treatment phase where participants will be enrolled and allocated to treatment cohorts based on their body weight at baseline. The dose and dosing regimens selected for SC administration in this pediatric population are intended to achieve a similar average exposure as observed with the weekly 200 mg SC dosing regimen in adult SLE patients. Part B is an optional 40-week open-label continuation phase, open to all participants who have completed Part A. Dosing of SC belimumab may continue at the same frequency in Part B or may require a change in frequency according to changes in participant body weight. The total duration of the study will be 68 weeks including a 12-Week open label treatment phase (Part A), an optional 40-week open-label continuation phase (Part B) and 16-week follow-up.
Primary Outcome
Blood samples were collected for measurement of serum concentrations of belimumab. Observed belimumab concentrations at Week 12 is presented.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Belimumab
Study Locations (11)
Other
- GSK Investigational Site - Rosario
- GSK Investigational Site - Berlin
- GSK Investigational Site - Saint Augustin
- GSK Investigational Site - Kagoshima
- GSK Investigational Site - Kanagawa
- GSK Investigational Site - San Luis Potosí City
- GSK Investigational Site - Rotterdam
- GSK Investigational Site - Barcelona
- GSK Investigational Site - Madrid
- GSK Investigational Site - Valencia
Ohio
- GSK Investigational Site - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-11-28 |
| Est. Completion | 2027-04-26 |
| Phase | Phase 2 |
What the registry record for NCT04179032 still lists
NCT04179032 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 1 intervention - of which Belimumab is the first listed.
NCT04179032 lists 11 locations in 2 states (Other, Ohio).
Frequently Asked Questions
What is clinical trial NCT04179032 about?
NCT04179032 is a clinical study titled "Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)". The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and pharmacodynamics (PD) of repeat doses of 200 milligrams per milliliter (mg/mL) belimumab administered via SC injection in pediatric participants 5 to 17 years of age with SLE on a background of standard of care therapy. ...
What is the current status of trial NCT04179032?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2019-11-28. Estimated completion is 2027-04-26.
What conditions does trial NCT04179032 study?
This clinical trial studies the following conditions: Systemic Lupus Erythematosus.
What interventions are being tested in trial NCT04179032?
The interventions under investigation include: Belimumab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04179032?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04179032 being conducted?
This trial has 11 study locations across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Systemic Lupus Erythematosus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04179032's enrollment target sits among peer trials
25 87th of 99 higher than 13 of 99 other Systemic Lupus Erythematosus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Systemic Lupus Erythematosus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
RECRUITING · Phase 2
-
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
RECRUITING · Phase 2
-
Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
RECRUITING · Phase 2
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI